FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2073534246> ?p ?o ?g. }

• W2073534246 abstract "Cycloset is a quick-release formulation of bromocriptine mesylate, a dopamine agonist, which in animal models of insulin resistance and type 2 diabetes acts centrally to reduce resistance to insulin- mediated suppression of hepatic glucose output and tissue glucose disposal. In such animals, bromocriptine also reduces hepatic triglyceride synthesis and free fatty acid mobilization, manifesting decreases in both plasma triglycerides and free fatty acids. In clinical trials, morning administration of Cycloset either as monotherapy or adjunctive therapy to sulfonylurea or insulin reduces HbA1c levels relative to placebo by 0.55-1.2. Cycloset therapy also reduces plasma triglycerides and free fatty acid by approximately 25% and 20%, respectively, among those also receiving sulfonylurea therapies. The effects of once-daily morning Cycloset therapy on glycemic control and plasma lipids are demonstrable throughout the diurnal portion of the day (7 a.m. to 7 p.m.) across postprandial time points.3,095 individuals were randomized in a 2:1 ratio into a one year trial aimed to assess the safety and efficacy of Cycloset compared to placebo among individuals receiving a variety of treatments for type 2 diabetes. Eligibility criteria for this randomized placebo controlled trial included: age 30-80, HbA1c <or= 10%, diabetes therapeutic regimen consisting of diet or no more than two hypoglycemic agents or insulin with or without one additional oral agent (usual diabetes therapy; UDT). The primary safety endpoint will test the hypothesis that the rate of all-cause serious adverse events after one year of usual diabetes therapy (UDT) plus Cycloset is not greater than that for UDT plus placebo by more than an acceptable margin defined as a hazard ratio of 1.5 with a secondary endpoint analysis of the difference in the rate of serious cardiovascular events, (myocardial infarction, stroke, coronary revascularization or hospitalization for or angina or congestive heart failure). Efficacy analyses will evaluate effects of Cycloset versus placebo on change from baseline in HbA1c, fasting glucose, body weight, waist circumference, blood pressure and plasma lipids.This study will extend the current data on Cycloset safety, tolerability and efficacy in individuals with type 2 diabetes to include its effects in combination with thiazolodinediones, insulin secretagogues, metformin, alpha-glucosidase inhibitors and exogenous insulin regimens.clinical trials.gov NCT00377676." @default.
• W2073534246 created "2016-06-24" @default.
• W2073534246 creator A5012460833 @default.
• W2073534246 creator A5035093618 @default.
• W2073534246 creator A5061962090 @default.
• W2073534246 creator A5084493896 @default.
• W2073534246 creator A5087681248 @default.
• W2073534246 date "2007-06-25" @default.
• W2073534246 modified "2023-10-16" @default.
• W2073534246 title "A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset™ or placebo" @default.
• W2073534246 cites W1959679999 @default.
• W2073534246 cites W1970993456 @default.
• W2073534246 cites W1972779667 @default.
• W2073534246 cites W2005386475 @default.
• W2073534246 cites W2012910225 @default.
• W2073534246 cites W2047557486 @default.
• W2073534246 cites W2074188086 @default.
• W2073534246 cites W2081333049 @default.
• W2073534246 cites W2120931772 @default.
• W2073534246 cites W2141917949 @default.
• W2073534246 cites W2161674848 @default.
• W2073534246 cites W280679252 @default.
• W2073534246 cites W4213243604 @default.
• W2073534246 doi "https://doi.org/10.1186/1472-6823-7-3" @default.
• W2073534246 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1924849" @default.
• W2073534246 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17592632" @default.
• W2073534246 hasPublicationYear "2007" @default.
• W2073534246 type Work @default.
• W2073534246 sameAs 2073534246 @default.
• W2073534246 citedByCount "50" @default.
• W2073534246 countsByYear W20735342462012 @default.
• W2073534246 countsByYear W20735342462013 @default.
• W2073534246 countsByYear W20735342462014 @default.
• W2073534246 countsByYear W20735342462015 @default.
• W2073534246 countsByYear W20735342462016 @default.
• W2073534246 countsByYear W20735342462018 @default.
• W2073534246 countsByYear W20735342462019 @default.
• W2073534246 countsByYear W20735342462020 @default.
• W2073534246 countsByYear W20735342462022 @default.
• W2073534246 countsByYear W20735342462023 @default.
• W2073534246 crossrefType "journal-article" @default.
• W2073534246 hasAuthorship W2073534246A5012460833 @default.
• W2073534246 hasAuthorship W2073534246A5035093618 @default.
• W2073534246 hasAuthorship W2073534246A5061962090 @default.
• W2073534246 hasAuthorship W2073534246A5084493896 @default.
• W2073534246 hasAuthorship W2073534246A5087681248 @default.
• W2073534246 hasBestOaLocation W20735342461 @default.
• W2073534246 hasConcept C126322002 @default.
• W2073534246 hasConcept C134018914 @default.
• W2073534246 hasConcept C142724271 @default.
• W2073534246 hasConcept C168563851 @default.
• W2073534246 hasConcept C197934379 @default.
• W2073534246 hasConcept C203092338 @default.
• W2073534246 hasConcept C204787440 @default.
• W2073534246 hasConcept C27081682 @default.
• W2073534246 hasConcept C2777180221 @default.
• W2073534246 hasConcept C2777391703 @default.
• W2073534246 hasConcept C2778199505 @default.
• W2073534246 hasConcept C2778375690 @default.
• W2073534246 hasConcept C2778854520 @default.
• W2073534246 hasConcept C2779306644 @default.
• W2073534246 hasConcept C2780473172 @default.
• W2073534246 hasConcept C2781413609 @default.
• W2073534246 hasConcept C555293320 @default.
• W2073534246 hasConcept C71924100 @default.
• W2073534246 hasConcept C98274493 @default.
• W2073534246 hasConceptScore W2073534246C126322002 @default.
• W2073534246 hasConceptScore W2073534246C134018914 @default.
• W2073534246 hasConceptScore W2073534246C142724271 @default.
• W2073534246 hasConceptScore W2073534246C168563851 @default.
• W2073534246 hasConceptScore W2073534246C197934379 @default.
• W2073534246 hasConceptScore W2073534246C203092338 @default.
• W2073534246 hasConceptScore W2073534246C204787440 @default.
• W2073534246 hasConceptScore W2073534246C27081682 @default.
• W2073534246 hasConceptScore W2073534246C2777180221 @default.
• W2073534246 hasConceptScore W2073534246C2777391703 @default.
• W2073534246 hasConceptScore W2073534246C2778199505 @default.
• W2073534246 hasConceptScore W2073534246C2778375690 @default.
• W2073534246 hasConceptScore W2073534246C2778854520 @default.
• W2073534246 hasConceptScore W2073534246C2779306644 @default.
• W2073534246 hasConceptScore W2073534246C2780473172 @default.
• W2073534246 hasConceptScore W2073534246C2781413609 @default.
• W2073534246 hasConceptScore W2073534246C555293320 @default.
• W2073534246 hasConceptScore W2073534246C71924100 @default.
• W2073534246 hasConceptScore W2073534246C98274493 @default.
• W2073534246 hasIssue "1" @default.
• W2073534246 hasLocation W20735342461 @default.
• W2073534246 hasLocation W20735342462 @default.
• W2073534246 hasLocation W20735342463 @default.
• W2073534246 hasLocation W20735342464 @default.
• W2073534246 hasLocation W20735342465 @default.
• W2073534246 hasLocation W20735342466 @default.
• W2073534246 hasOpenAccess W2073534246 @default.
• W2073534246 hasPrimaryLocation W20735342461 @default.
• W2073534246 hasRelatedWork W138803513 @default.
• W2073534246 hasRelatedWork W1986132654 @default.
• W2073534246 hasRelatedWork W2010140898 @default.
• W2073534246 hasRelatedWork W2064328592 @default.
• W2073534246 hasRelatedWork W2080135029 @default.
• W2073534246 hasRelatedWork W2082140668 @default.

• next